BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Du W, Hurdiss DL, Drabek D, Mykytyn AZ, Kaiser FK, González-Hernández M, Muñoz-Santos D, Lamers MM, van Haperen R, Li W, Drulyte I, Wang C, Sola I, Armando F, Beythien G, Ciurkiewicz M, Baumgärtner W, Guilfoyle K, Smits T, van der Lee J, van Kuppeveld FJM, van Amerongen G, Haagmans BL, Enjuanes L, Osterhaus ADME, Grosveld F, Bosch BJ. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern. Sci Immunol 2022;:eabp9312. [PMID: 35471062 DOI: 10.1126/sciimmunol.abp9312] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Kumar S, Patel A, Lai L, Chakravarthy C, Valanparambil R, Reddy ES, Gottimukkala K, Davis-Gardner ME, Edara VV, Linderman S, Nayak K, Dixit K, Sharma P, Bajpai P, Singh V, Frank F, Cheedarla N, Verkerke HP, Neish AS, Roback JD, Mantus G, Goel PK, Rahi M, Davis CW, Wrammert J, Godbole S, Henry AR, Douek DC, Suthar MS, Ahmed R, Ortlund E, Sharma A, Murali-Krishna K, Chandele A. Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody. Sci Adv 2022;8:eadd2032. [PMID: 36197988 DOI: 10.1126/sciadv.add2032] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Hsu FF, Liang KH, Kumari M, Chen WY, Lin HT, Cheng CM, Tao MH, Wu HC. An efficient approach for SARS-CoV-2 monoclonal antibody production via modified mRNA-LNP immunization. Int J Pharm 2022;:122256. [PMID: 36198358 DOI: 10.1016/j.ijpharm.2022.122256] [Reference Citation Analysis]
3 Huang Q, Han X, Yan J. Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies. Emerging Microbes & Infections. [DOI: 10.1080/22221751.2022.2125348] [Reference Citation Analysis]
4 Tang H, Ke Y, Wang L, Wu M, Sun T, Zhu J. Recombinant Decoy Exhibits Broad Protection against Omicron and Resistance Potential to Future Variants. Pharmaceuticals 2022;15:1002. [DOI: 10.3390/ph15081002] [Reference Citation Analysis]
5 Verkhivker G, Agajanian S, Kassab R, Krishnan K. Integrating Conformational Dynamics and Perturbation-Based Network Modeling for Mutational Profiling of Binding and Allostery in the SARS-CoV-2 Spike Variant Complexes with Antibodies: Balancing Local and Global Determinants of Mutational Escape Mechanisms. Biomolecules 2022;12:964. [PMID: 35883520 DOI: 10.3390/biom12070964] [Reference Citation Analysis]
6 Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect Dis 2022:S1473-3099(22)00311-5. [PMID: 35803289 DOI: 10.1016/S1473-3099(22)00311-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
7 Verkhivker G, Agajanian S, Kassab R, Krishnan K. Integrating Conformational Dynamics and Perturbation-Based Network Modeling for Mutational Profiling of Binding and Allostery in the SARS-CoV-2 Spike Variant Complexes with Antibodies: Balancing Local and Global Determinants of Mutational Escape Mechanisms.. [DOI: 10.1101/2022.06.17.496646] [Reference Citation Analysis]